Insulin Treatment Post Myocardial Infarction: The Digami Study

  • Klas Malmberg
  • Anna Norhammar
  • Lars Rydén
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 498)


During a review of the unselected diabetic patients with acute MI at our institution in the mid 80’s, we found that 22% of our patients had diabetes, and an even more striking finding was that more than 50% have died within one year1. One can argue that this was before the introduction of modern treatment strategies but even recent data confirm an almost doubled 35-day mortality rate in diabetic patients who have suffered an acute MI compared to non-diabetics2. After that we planned for the DIGAMI study which was completed in 1994. The results of this study have been published elsewhere. 3,4,5


Acute Myocardial Infarction Insulin Treatment Glucose Oxidation Infusion Group Intensive Insulin Treatment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Malmberg K, Ryden L. Myocardial infarction in patients with diabetes mellitus. Eur Heart J 1988; 9: 256–64Google Scholar
  2. 2.
    Woodfield SL, Lundergan CF, Reiner JS, et al. Angiographie findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol 1996;28:1661–1669PubMedCrossRefGoogle Scholar
  3. 3.
    Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, Wedel H, Welin L. A randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction: Effects on one year mortality. J Am Coll Cardiol 1995; 26:57–65PubMedCrossRefGoogle Scholar
  4. 4.
    Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wedel H. Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. Eur Heart J 1996; In pressGoogle Scholar
  5. 5.
    Malmberg K. Prospective randomized study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus. British Medical Journal 1997; 314: 1512–1515PubMedCrossRefGoogle Scholar
  6. 6.
    Stone P, Muller J, Hartwell T, Yourk B, Rutherford J, Parker C, Turi Z, Strauss W, Willerson J, Robertson T. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: Contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. J Am Coll Cardiol 1989; 14: 49–57PubMedCrossRefGoogle Scholar
  7. 7.
    Jaffe A, Spadaro J, Schechtman K, Roberts R, Geltman E, Sobel B. Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus. Am Heart J 1984; 108: 31–37PubMedCrossRefGoogle Scholar
  8. 8.
    Karlson BW, Herlitz J, Hjalmarson A. Prognosis of acute myocardial infarction in diabetic and non-diabetic patients. Diabet Med 1993; 10: 449–54PubMedCrossRefGoogle Scholar
  9. 9.
    Barbash GI, White HD, Modan M, Van der werf WF. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol 1993; 22: 707–713PubMedCrossRefGoogle Scholar
  10. 10.
    Fath-Ordoubadi F, Beatt K. Glucose-Insulin-Potassium therapy for treatment of acute myocardial infarction. An overview of randomized placebo controlled trials. Circulation 1997; 96: 1152–1156.PubMedCrossRefGoogle Scholar
  11. 11.
    Diaz R, Paolasso EA, Piegas LS et al. Metabolic modulation of acute myocardial infarction. The ECLA glucose-insulin-potassium pilot trial. Circulation 1998; 98: 2227–2234.PubMedCrossRefGoogle Scholar
  12. 12.
    Glucose-insulin-potassium in acute myocardial infarction. The time has come for a large, prospective trial. Apstein CS, Taegtmeyer H. Circulation 1997; 96: 1074–1077.Google Scholar
  13. 13.
    Jain SK, Nagi DK, Slavin BM, Lumb PJ, Yudkin JS. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycemic control. Diabet Med 1993; 10: 27–32PubMedCrossRefGoogle Scholar
  14. 14.
    Davi G, Catalan I, Avema M, Notarbartolo A, Sartrano A, Ciaboattoni G, Patrono C. Thromboxane biosynthesis and platelet function in type 2 diabetes mellitus. New Engl J Med 1990; 322:1769–1774PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Klas Malmberg
    • 1
  • Anna Norhammar
    • 1
  • Lars Rydén
    • 1
  1. 1.Department of CardiologyKarolinska HospitalStockholmSweden

Personalised recommendations